Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis

References

• Richards RG, Sampson FC, Beard SM, Tappenden P. A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Tech Assess 2002;6(10):1-73
   PubMedGoogle Scholar
• Zajicek JP, Hobart JC, Slade A, et al. Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012;83:1125-32
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-19
   PubMed Web of Science ®Google Scholar
• Kavia RB, De Ridder D, Constantinescu CS, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010;16(11):1349-59
   PubMed Web of Science ®Google Scholar
• Stott CG, White L, Wright S, et al. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 2013;69:1135-47
   PubMed Web of Science ®Google Scholar
• Robson P. Abuse potential and psychoactive effects of d-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011;10(5):675-85
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163(7):1479-94
   PubMed Web of Science ®Google Scholar
• Russo EB, Burnett A, Hall B, Parker KK. Agonistic Properties of Cannabidiol at 5-HT1a Receptors. Neurochem Res 2005;30(8):1037-43
   PubMed Web of Science ®Google Scholar
• Liou GI, Auchampach JA, Hillard CJ, et al. Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor. Invest Ophthalmol Vis Sci 2008;49(12):5526-31
   PubMedGoogle Scholar
• O’Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 2010;215(8):611-16
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz J, Sagredo O, Pazos MR, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol 2013;75(2):323-33
   PubMed Web of Science ®Google Scholar
• Guy GW, Robson PJ. Phase I, open label, four-way crossover study to compare the pharmacokinetic profiles of a single dose of 20 mg of a cannabis based medicine extract (CBME) administered on 3 different areas of the buccal mucosa and to investigate the pharmacokinetics of CBME per oral in healthy male and female volunteers (GWPK0112). J Cannabis Ther 2003;3(4):79-120
   Google Scholar
• Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/Cannabidiol (Sativex): a Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis. Drugs 2014;74:563-78
   PubMedGoogle Scholar
• Stott CG, White L, Wright S, et al. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 2013;69:1135-47
   PubMed Web of Science ®Google Scholar
• Karschner EL, Darwin WD, Goodwin RS, et al. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 2011;57(1):66-75
   PubMed Web of Science ®Google Scholar
• Stott CG, White L, Wright S, et al. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray. Eur J Clin Pharmacol 2013;69(4):825-34
   PubMed Web of Science ®Google Scholar
• Stott CG, White L, Wright S, et al. A phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of rifampicin, ketoconazole, and omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springer Plus 2013;2(1):236
   PubMedGoogle Scholar
• Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17(1):21-9
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26
   PubMed Web of Science ®Google Scholar
• Vaney C, Heinzel-Gutenbrunner M, Jobin P Tschopp F, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patient with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-24
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, Ratcliffe S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6
   PubMed Web of Science ®Google Scholar
• Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol 2013;260:285-95
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G, et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32(5):451-9
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S, et al. Sativex Spasticity Study Group. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-31
   PubMed Web of Science ®Google Scholar
• Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regime, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol 2013;260:984-77
   PubMed Web of Science ®Google Scholar
• Podda G, Constantinescu CS. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis. Expert Opin Biol Ther 2012;12(11):1517-31
   PubMed Web of Science ®Google Scholar
• Aragona M, Onesti E, Tomassini V, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharm 2009;32:41-7
   PubMed Web of Science ®Google Scholar
• Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler 2012;18:219-28
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD Oromucosal Spray, Sativex ®) in clinical practice – results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 2014;71:271-9
   PubMed Web of Science ®Google Scholar
• Koehler J, Feneberg W, Meier M, Pöllman W. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci 2014;124(9):652-6
   PubMed Web of Science ®Google Scholar
• Garcia-Merino A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev Neurother 2013;13(3 Suppl 1):9-13
   PubMed Web of Science ®Google Scholar
• Rekand T. THC: CBD spray and MS spasticity symptoms: data from latest studies. Eur Neurol 2014;71(suppl 1):4-9
   PubMedGoogle Scholar
• Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2014;82(12):1083-92
   PubMed Web of Science ®Google Scholar
• Sánchez AJ, García-Merino A. Neuroprotective agents: cannabinoids. Clin Immunol 2012;142(1):57-67
   PubMedGoogle Scholar
• Zajicek J, Ball S, Wright D, et al. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 2013;12(9):857-65
   PubMed Web of Science ®Google Scholar